A Comparative Clinical Study on Vatariguggulu and Panchakarma Therapy with Special Reference to Kshara Basti and Virechana Karma in the Management of Amavata (Rheumatoid Arthritis)

Ashis KD1* and Tuhin KB2

1Department of Panchakarma, Institute of Post Graduate Ayurvedic Education and Research, India
2Department of Kayachikitsa, J. B. Roy State Ayurvedic Medical College & Hospital, India

*Corresponding author: Ashis Kumar Das, Department of Panchakarma, Institute of Post Graduate Ayurvedic Education and Research, Kolkata 700009, India, Tel: +91 9433063678; E-mail: ashisdas101080@gmail.com

Abstract

In the whole world, rheumatic diseases are the commonest cause of physical & mental crippling condition in the society with rheumatoid arthritis is sharing the lion portion [1]. Important role in the management of this crippling disease has been described in Ayurveda from ancient time. It appears from the point of view of modern medical sciences that Amavata can be simulated with rheumatoid arthritis in its clinical appearance. In spite of tremendous development of modern medical sciences, modern drugs for the management of rheumatoid arthritis shows serious side effects like gastritis, gastric ulcers, immune depression, decalcifications, hyperglycemia, etc. and ultimately no drug is found to be effective after a certain period of therapeutics. Panchakarma therapy is one of the important branches of Ayurveda, which deals mainly with purification of the aggravated dosas (pathological state of body humors) from the human system. Amavata, being a disease that develops due to involvement of ‘Ama’ and ‘Vata’ in particular. Vasti (enema) therapy is a special branch of Panchakarma, usually administered for elimination of Vata. Virechana or purgation is another important therapy under Panchakarma which is mainly administered mainly to eliminate Ama dosa in the present context. Beside, conventional panchakarma therapies like Vasti and Virechana, conservative conventional pacification therapies with Vatariguggulu was also added. Results were found significant (p<0.05) by combination with Panchakarma along with relevant pacification therapy.

Keywords: Amavata; Rheumatoid Arthritis; Kshara Basti; Virechana; Vatariguggulu
Abbreviations: SOP: Standard Operation Procedure; RA: Rheumatoid Arthritis

Introduction

Āmavāṭa is manifested due to dual inter action between “Āma” and ‘Vāta’. Ama concept mimics with elevation of Kapha dosa due to indolence of Jatharagni or Pachaka Pitta. Vata itself represents motion. In the disease "Amavāṭa" the dosa ‘Vata’ is encapsulated by kapha producing features of joint pain, swelling etc. Main principles of Amavāṭa management includes Langhana (lightering therapy), Swedana (fomentration), Tikta Rasa (bitter substances), Dipana (stomachic) and Katu rasa (pungent taste), all of which helps to pacify Kapha dosha in the form of ‘Āma’ so that encapsulated “Vata” becomes free [1]. This therapy is followed by Virechana Karma (purgation) to eliminate Pitta dosa situated within Rakta dhatu of sira that lies in Sandhi. Finally Snehanasa as purvakarma and Vasti as pradhan karma (main purification therapeutic), may help to eliminate Vata so that the disease process will be under control.

According to Madhavkara, the disease ‘Amavāṭa’ is characterized by manifestation of the symptoms like stiffness (Stabhdhatwa) and heaviness/ swelling (Gurutwa) of Sandhis (joints) [2]. Amavāṭa is a disease under the category of Vata-Kaphaja disorders. The clinical presentation of Amavāṭa closely mimics with the special variety of rheumatological disorders viz. rheumatoid arthritis, in accordance with their similarities on clinical features. These were selected on the basis of the criteria designed by American Rheumatological Society as mentioned in the inclusion criteria.

“Panchakarma therapy” is such a unique module of management described in Ayurveda, which can eliminate the causative pathogens (Dosa-Nir-Harana) from the system for complete eradication of disease process. In the present study, Virechana karma and Kshar Basti are selected for the Sanshodhana (purification) process while, Vatariguggulu was selected as Shamana (pacification) Yoga. Both of these procedures are mentioned in Chikitsa Sutra described by Chakradatta.

Vatariguggulu is applied as maintenance therapy in Amavāṭa which is kriechasadhya (hardly curable) in nature because composition mainly dominated by ushna virya combating vata dosa so the chance of reversion is inhibited [3]. According to the modern concept of rheumatoid arthritis, IgG and IgM undergo for an anti-immune reaction in a HLA- DR4 compatible patients leading to alteration of type II collagen synthesis [4]. Panchakarma therapy being a unique purification therapy that seems to have role in detoxification of body enzyme and reactions may arrest auto-immune reaction and thereby control disease process. Guggulu as one the important ingredient of vatariguggulu is reported to have anti-inflammator effect.

Aims & Objectives

i) To develop standard operation procedure (SOP) of certain panchakarma therapy in Amavāṭa (Rheumatoid Arthritis)

ii) To evaluate safety and efficacy of certain Panchakarma therapy in Amavāṭa (RA)

iii) To establish “modus operandi” on the basis of comparative pharmacodynamics between Ayurveda and Modern medicine.

Materials and Methods

Selection of Patients

Complete 90 cases of ‘Amavāṭa’ vis-à-vis ‘rheumatoid arthritis were selected irrespective of sex, religion, habitat, income status, occupation etc. from the OPD and IPD of J. B. Roy State Ayurvedic Medical College and Hospital, Kolkata and other referred hospital as well as other clinics. All the patients were registered at J. B. Roy State Ayurvedic Medical College and Hospital, Kolkata for final evaluation. Patients fulfilling at least four out of seven criteria of Rheumatoid arthritis as per American Rheumatism Association 1988 revised guidelines, will be selected for the present research programme [5]. All the patients will be included according WHO-Helsinki protocol after taking their informed consent.

Study Variable

Variability of study extended in terms of age and duration of suffering with severity without having any serious connected associated diseases like cardiac problem, diabetes mellitus, pregnancy, hepatic disorders, renal diseases, malignancies, etc.

Sampling Design

The study was performed in three treatment groups as follows –

Ashis KD and Tuhin KB. A Comparative Clinical Study on Vatariguggulu and Panchakarma Therapy with Special Reference to Kshara Basti and Virechana Karma in the Management of Amavāṭa (Rheumatoid Arthritis). J Nat Ayurvedic Med 2017, 1(2): 000110.

Copyright© Ashis KD and Tuhin KB.
| Treatment group          | No. of Patients | Treatment Schedule                       |
|-------------------------|----------------|------------------------------------------|
| Group-I (Guggula 3 g/day for 15 days) | 30 Patients | Kshara Vasti along with Vatari          |
| Group - II (3 g/day for 15 days)     | 30 Patients | Virechana karma with Vatari Guggula     |
| Group - III (by Virechana for 15 days along with Vatari Guggula 3 g/day for 30 days) | 30 Patients | Kshara Vasti for 15 days followed       |

### Objective Parameters
Following objective/ laboratory parameters were taken in present research programme –

1. Routine blood examination including TEC, TLC, DLC, ESR, Hb%
2. Skiagraphy of joints involved
3. Rheumatoid factors

### Statistical Analysis
All the data were statistically analysed using SPSS-Win package systems.

### Drug Review
In Ayurveda, dravya (medicament) has been emphasized as the second place amongst the four-fold factors i.e. Bhisaka (physician), Dravya (both drugs and food substance), Upasthata (attendant) and Rogi (patient) [6]. While treating a patient the selection of Ausadha comes after the proper diagnosis of the patient. It should be suitable to the patient and against the disease as well as dosa involved. The selection of drug was made accordingly for keeping the three dosas in balance state. The drugs in the present research work, is based on the above foundation.

Vatarguggulu has been selected due to its Katu (pungent) and Tikta (bitter) Rasa, Ushna Virya, Rasayana Prabhava, Ama Pachana and Vata-kaphashamana properties [3]. It helps to disrupt the pathogenesis (Samprapti Vighatana) of Amavata. Vatarguggulu is applied as maintenance therapy in Amavata which is kricchasadhya in nature because composition mainly dominated by ushna virya combating vata dosa so the chance of reversion is inhibited [7]. According to the modern concept of Rheumatoid arthritis IgG and IgM undergo for an anti-immune reaction in a HLA- DR4 compatible patients leading to alteration of type II collagen synthesis. Panchakarma therapy being a unique purification therapy that seems to have role in detoxification of body enzyme and reactions may arrest auto-immune reaction and thereby control disease process. Guggulu as one the important ingredient of vatariguggulu is reported to have anti-inflammatory effect.

Principal ingredients of Vatariguggulu are Eranda Taila (oil prepared from *Ricinus communis* Linn), Shuddha Gandhaka (sulphur), Shuddha Guggulu (*Commiphora mukul*), Haritaki (*Terminalia chebula*), Bibhitaka(*Terminalia bellerica*) and Amalaki (*Emblica officinalis*). The vatariguggulu was prepared in the pharmacy department of the host institute by conventional classical method.

The fruits of Amlaki are astringent, cooling, anodyne, carminative, digestive, stomachic, laxatives and tonic. Pharmacologically it is antioxidant, anti-inflammatory, antibacterial, antiulcer etc., [8]. The fruits of Bibhitaka is reported to have Shothahara, Deepana, Anulomana, Keshya, Svarya, Krimighna, Raktashodhaka etc in nature. Pharmacologically it is anti fungal, purgative, antihistaminic, antistress in nature. Fruits of Haritaki (*Terminalia chebula* Linn) is used as Shotha-Vedanayukta Vikara (diseases associated with pain), Agnimandya, Shula, anaha,etc. Pharmacologically it has effect on oxidative stress [9].

Gandhaka is noted in Ayurveda widely for different formulation. Gandhaka is described to have kaphavatahara & pitta samak properties. Eranda taila is Kapha-vata Shamaka. It is Shothahara, Deepana, Bhedana, Amashodhana, Srotovishodhana, Vrshya, Kushtaghna, Angamardaprashamana, Shukrashodhana etc. Guggulu, the main ingredient of Vatariguggulu, is Lekhana, Ropana, Vedanasthapana, Nadibalya, Deepana, Saraka, Mutrala, Raktavardhaka, Rasayana, Bhagnasandhanaka, Jantughna and Pramehahara in properties.

Pharmacologically gum resin showed different pharmacological properties like astringent, expectorant, aphrodisiac, demulcent, carminative, antispasmodic, emmenagogue, blood enhancer, anti-snake venom and anti-scorpion sting, anti-fertility, arthritis, leprosy, in impotence and sterility, in liver disorder and hemiplagia, hypocholesteremic, hypolipidaemic, atherosclerosis, thyroid stimulating, psoriasis and cardiac ischaemia.

---

Ashis KD and Tuhin KB. A Comparative Clinical Study on Vatariguggulu and Panchakarma Therapy with Special Reference to Kshara Basti and Virechana Karma in the Management of Amavata (Rheumatoid Arthritis). *J Nat Ayurvedic Med* 2017, 1(2): 000110.
Inclusion Criteria

i) Patient having age between 20–50 years
ii) Patients fulfill at least four out of seven criteria of American Rheumatism Association (1988) –
   • Morning stiffness lasting for more than one hours
   • Arthritis of three or more joints
   • Arthritis of hand joints
   • Symmetrical arthritis
   • Rheumatic nodules
   • Presence of rheumatoid factor
   • Radiological changes (hand and wrist)

Rheumatoid arthritis is diagnosed if a patient carried out at least four of the above criteria for at least last 6 weeks.

iii) Patients of both sexes, irrespective of religion, habitat, income status, occupation, etc.
iv) Patients willing to include themselves in the study through informed consent form.

Exclusion Criteria

i) Patients having age below 20 and above 50 years
ii) Patients of rheumatoid arthritis with high titres of rheumatoid factor, insidious onset of disease, early development of nodules, extra-articular manifestation, severe functional deformities, etc.
iii) Patients suffering with diseases like cardiac problem, diabetes mellitus, hepatic disorders, renal diseases, malignancies, etc.
iv) Pregnant mother
v) Patients who does not fulfill at least four out of seven criteria of rheumatoid arthritis
vi) Patients not willing to include themselves in the study through informed consent form

Recent Diagnostic Assessment

According to recent criteria for assessment of RA on the basis of arbitrary scoring is described in the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis, the diagnosis is done by following scoring system [10].

| Score | Target population (Who should be tested?): Patients who |
|-------|----------------------------------------------------------|
|       | 1) have at least 1 joint with definite clinical synovitis (swelling) |
|       | 2) with the synovitis not better explained by another disease† |
|       | Classification criteria for RA |
|       | (score-based algorithm: add score of categories A–D; a score of _6/10 is needed for classification of a patient as having definite RA) |
|       | A. Joint involvement |
|       | 1 large joint | 0 |
|       | 2-10 large joints | 1 |
|       | 1-3 small joints (with or without involvement of large joints) | 2 |
|       | 4-10 small joints (with or without involvement of large joints) | 3 |
|       | >10 joints (at least 1 small joint) | 5 |
|       | B. Serology (at least 1 test result is needed for classification) |
|       | Negative RF and negative ACPA | 0 |
|       | Low-positive RF or low-positive ACPA | 2 |
|       | High-positive RF or high-positive ACPA | 3 |
|       | C. Acute-phase reactants (at least 1 test result is needed for classification) |
|       | Normal CRP and normal ESR | 0 |
|       | Abnormal CRP or abnormal ESR | 1 |
|       | D. Duration of symptoms<6 weeks | 0 |
|       | ≥6 weeks | 1 |

Patients with a score of <6/10 are not classifiable as having RA, their status can be reassessed and the criteria might be fulfilled cumulatively over time.
Summary of the Previous Progress Reports

First year (2013-2014): An attempt was taken for inclusion of more numbers of patients suffering with Amavata (Rheumatoid Arthritis) in different treatment schedules. A total number of 17 patients were included in the year 2013-2014, who were divided into 3 groups with distribution of 10 patients in group A, 3 Patients in Group B and 4 Patient in Group C. No definite interpretation were drawn regarding the effect of drugs in the first year as the duration of therapy was very minimum.

Second year (2014-2015): A total number of 39 patients were enrolled including 17 patients of previous year. Distribution of 39 patients were done with 14 patient in group ‘A’, 12 patients in group ‘B’ and 13 patient in group ‘C’. In accordance with this studies it was observed that remarkable improvementy were observed in the patient of group ‘A’ treated with Kshar Vasti along with Vatari Guggulu 3gms per day for 15 days.

Third year (2015-2016): Total 63 patients including 39 patients of previous year were enrolled in this year. They were distributed with 22 patients in group ‘A’, 21 patients in group ‘B’ and 20 patients in group ‘C’. In accordance with this studies it was observe that remarkable improvement of different symptoms on the basis of arbitrary scoring system in the patient of group ‘A’ treated with Kshar Vasti along with Vatari Guggulu 3gms per day for 15 days. However, moderate results were observed in groups ‘B’ & ‘C’. The research work was continued with involvement of more number of patients to draw a consistent conclusion.

Final result: In response to above results, the study continued till September 2016 for inclusion of more number of patients including previous 39 patients. A total 90 patients were included up to the period of September 2016, who were distributed with 30 patient in group ‘A’, 30 patients in group ‘B’ and 30 patient in group ‘C’. Result of the study is depicted from table 1 to table 14.

### Table 1: Effect of different therapies on cardinal features of Sandhishula (pain in joints) of left side in Amavata (Rheumatoid arthritis) on group A, B & C (n=90).

| Criteria Sandhishula | Group ‘A’ (n=30) | Group ‘B’ (n=30) | Group ‘C’ (n=30) |
|----------------------|------------------|------------------|------------------|
|                      | BT   | AT   | d±SE  | BT   | AT   | d±SE  | BT   | AT   | d±SE  |
| Left Wrist           | 2.20 | 1.10 | 1.10±0.09* (n=26) | 2.70 | 1.20 | 1.50±0.11* (n=14) | 2.50 | 0.40 | 3.10±0.90* (n=9) |
| Left Shoulder        | -    | -    | -     | 0.54 | 0.18 | 0.36±0.24* (n=4)  | -    | -    | -     |
| Left Knee            | 1.05 | 0.40 | 0.64±0.35* (n=18) | 1.10 | 0.10 | 1.00±0.24* (n=15) | 1.00 | 0.09 | 0.90±0.17* (n=11) |
| Left Ankle           | 1.70 | 0.60 | 1.10±0.26* (n=21) | 1.45 | 0.09 | 1.36±0.21* (n=11) | 1.45 | 0.09 | 1.36±0.13* (n=11) |

Legend: BT = Before Treatment, AT = After Treatment, d±SE = Mean differences ± Standard Error of Mean, * p<0.001

Table 1: Effect of different therapies on cardinal features of Sandhishula (pain in joints) of left side in Amavata (Rheumatoid arthritis) on group A, B & C (n=90).
A Comparative Clinical Study on Vatariguggulu and Panchakarma Therapy with Special Reference to Kshara Basti and Virechana Karma in the Management of Amavata (Rheumatoid Arthritis) in group A, B & C (n=90).

### Table 2: Effect of therapy on cardinal features in joints of right side in Amavata (Rheumatoid arthritis) in group A, B & C (n=90).

| Criteria        | Group ‘A’ (n=30) | Group ‘B’ (n=30) | Group ‘C’ (n=30) |
|-----------------|------------------|------------------|------------------|
|                 | BT   | AT   | d±SE  | BT   | AT   | d±SE  | BT   | AT   | d±SE  |
| Left Wrist      | 2.70 | 1.20 | 1.50 ± 0.11* (n=21) | 2.70 | 1.20 | 1.50 ± 0.13* (n=14) | 2.50 | 0.80 | 1.70 ± 0.70* (n=9) |
| Left Shoulder   | 0.90 | 0.10 | 0.60 ± 0.15* (n=16) | 1.10 | 0.30 | 0.80 ± 0.20* (n=15) | 1.00 | 0.27 | 0.72 ± 0.14* (n=6) |
| Left Knee       | 0.81 | 0.09 | 0.72±0.16* (n=15)  | 1.40 | 0.64 | 0.82±0.09* (n=11)  | 1.45 | 0.45 | 1.00±0.10* (n=11) |
| Left Ankle      | 1.45 | 0.09 | 1.36 ± 0.12* (n=21) | 1.45 | 0.36 | 1.09 ± 0.19* (n=11) | 1.45 | 0.45 | 1.00 ± 0.10* (n=11) |

### Table 3: Effect of therapy on cardinal features in joints of left side in Amavata (Rheumatoid arthritis) in group A, B & C (n=90).

| Criteria        | Group ‘A’ (n=30) | Group ‘B’ (n=30) | Group ‘C’ (n=30) |
|-----------------|------------------|------------------|------------------|
|                 | BT   | AT   | d±SE  | BT   | AT   | d±SE  | BT   | AT   | d±SE  |
| Left Wrist      | 2.70 | 1.20 | 1.50 ± 0.12* (n=21) | 2.70 | 1.20 | 1.50 ± 0.19* (n=11) | 2.27 | 0.81 | 1.45 ± 0.73* (n=9) |
| Left Shoulder   | 0.80 | 0.10 | 0.50 ± 0.15* (n=16) | 1.10 | 0.50 | 0.60 ± 0.18* (n=11) | 1.00 | 0.45 | 0.54 ± 0.27* (n=6) |
| Left Knee       | 0.72 | 0.27 | 0.54 ± 0.12* (n=15)  | 1.45 | 0.91 | 0.55 ± 0.16* (n=11)  | 1.45 | 0.36 | 1.09 ± 1.00* (n=11) |
| Left Ankle      | 0.60 | 0.00 | 0.60±0.05* (n=06)    |             | 1.20 | 1.50±0.12* (n=14)    | 2.27 | 1.18 | 1.09±0.45* (n=9)    |

### Table 4: Effect of therapy on Sandhishotha in joints of right side in Amavata (Rheumatoid arthritis) in group A, B & C (n=90).

| Criteria        | Group ‘A’ (n=30) | Group ‘B’ (n=30) | Group ‘C’ (n=30) |
|-----------------|------------------|------------------|------------------|
|                 | BT   | AT   | d±SE  | BT   | AT   | d±SE  | BT   | AT   | d±SE  |
| Left wrist      | 2.7  | 1.2  | 1.50±0.09* (n=21)   | 2.70 | 1.20 | 1.50±0.12* (n=14) | 2.27 | 1.18 | 1.09±0.45* (n=9) |
| Left elbow      | 0.60 | 0.00 | 0.60±0.55* (n=06)   |             | 1.20 | 1.50±0.12* (n=14) | 2.27 | 1.18 | 1.09±0.45* (n=9) |
A Comparative Clinical Study on Vatariguggulu and Panchakarma Therapy with Special Reference to Kshara Basti and Virechana Karma in the Management of Amavata (Rheumatoid Arthritis).

Table 5: Effect of therapy on cardinal features in joints of left side in Amavata (Rheumatoid arthritis) in group A, B & C. (n=90).

| Criteria     | Group ‘A’ (n=30) | Group ‘B’ (n=30) | Group ‘C’ (n=30) |
|--------------|------------------|------------------|------------------|
|              | BT   | AT   | d±SE   | BT   | AT   | d±SE   | BT   | AT   | d±SE   |
| Right wrist  | 2.70 | 1.20 | 1.50±0.11* | 2.70 | 1.20 | 1.50±0.19* | 2.27 | 1.18 | 1.09±0.64* |
|              | (n=21)|      |        | (n=14)|      |        | (n=09)|      |        |
| Right elbow  | 0.50 | 0.20 | 0.20±0.07* | -    | -    | -      | -    | -    | -      |
|              | (n=06)|      |        |      |      |        |      |      |        |
| Right shoulder | -    | -    | -      | 0.54 | 0.18 | 0.36±0.24* | -    | -    | -      |
| Knee         | 0.80 | 0.40 | 0.40±0.09* | 1.10 | 0.7  | 0.33±0.17* | 1.00 | 0.45 | 0.54±0.27* |
|              | (n=14)|      |        | (n=15)|      |        | (n=06)|      |        |
| Ankle        | 0.72 | 0.36 | 0.54±0.12* | 1.45 | 0.73 | 0.73±0.13* | 1.45 | 0.45 | 1.00±1.18* |
|              | (n=13)|      |        | (n=11)|      |        | (n=11)|      |        |

Table 6: Effect of therapy on cardinal features in joints of right side in Amavata (Rheumatoid arthritis) in group A, B & C. (n=90).

| Criteria     | Group ‘A’ (n=30) | Group ‘B’ (n=30) | Group ‘C’ (n=30) |
|--------------|------------------|------------------|------------------|
|              | BT   | AT   | d±SE   | BT   | AT   | d±SE   | BT   | AT   | d±SE   |
| Left wrist   | 2.70 | 1.20 | 1.50±0.09* | 2.70 | 1.20 | 1.50±0.18* | 2.27 | 0.90 | 1.36±0.54* |
|              | (n=11)|      |        | (n=14)|      |        | (n=09)|      |        |
| Right shoulder | -    | -    | -      | 0.72 | 0.45 | 0.27±0.21* | -    | -    | -      |
| Knee         | 0.60 | 0.30 | 0.30±0.08* | 1.10 | 0.40 | 0.70±0.21* | 1.00 | 0.27 | 0.72±0.45* |
|              | (n=06)|      |        | (n=15)|      |        | (n=06)|      |        |
| Ankle        | 0.36 | 0.09 | 0.27±0.08* | 1.45 | 0.82 | 0.64±0.14* | 1.45 | 0.36 | 1.09±0.81* |
|              | (n=05)|      |        | (n=11)|      |        | (n=11)|      |        |

Table 7: Effect of therapy on cardinal features in joints of left side in Amavata (Rheumatoid arthritis) in group A, B & C. (n=90).
A Comparative Clinical Study on Vatariguggulu and Panchakarma Therapy with Special Reference to Kshara Basti and Virechana Karma in the Management of Amavata (Rheumatoid Arthritis)

| Criteria Sparshasahyata | Group ‘A’ (n=30) | Group ‘B’ (n=30) | Group ‘C’ (n=30) |
|--------------------------|----------------|----------------|----------------|
| Right wrist              | 2.20 1.20      | 1.50±0.09*     | 1.50±0.17*     |
|                          | (n=10)         | (n=14)         | (n=09)         |
| Right shoulder           | - -            | 0.72 0.45      | 0.27±0.33*     |
|                          |                 | (n=04)         |                 |
| Knee                     | 0.60 0.40      | 0.40±0.12*     | 0.72±0.13*     |
|                          | (n=6)          | (n=15)         | (n=06)         |
| Ankle                    | 0.36 0.09      | 0.27±0.08*     | 0.36±0.15*     |
|                          | (n=5)          | (n=11)         | (n=11)         |

BT = Before Treatment, AT = After Treatment, d±SE = Mean differences ± Standard Error of Mean,* p<0.001
Table 8: Effect of therapy on cardinal features in joints of right side in Amavata (Rheumatoid arthritis) in group A, B & C. (n=90).

| General Symptoms | Group ‘A’ (n=30) | Group ‘B’ (n=30) | Group ‘C’ (n=30) |
|------------------|----------------|----------------|----------------|
|                  | BT  AT d±SE  | BT  AT d±SE  | BT  AT d±SE  |
| Angamarda        | 1.79 1.10    | 1.10±0.08*   | 1.64 0.93    |
|                  | (n=26)       | (n=17)       | (n=12)       |
| Trishna          | 0.76 0.23    | 0.52±0.13*   | 0.20 0.10    |
|                  | (n=12)       | (n=16)       | (n=01)       |
| Aruchi           | 1.00 0.50    | 0.50±0.32*   | 2.00 1.10    |
|                  | (n=15)       | (n=18)       | (n=18)       |
| Alasya           | 0.93 0.50    | 0.43±0.52*   | 0.80 0.40    |
|                  | (n=15)       | (n=15)       | (n=16)       |
| Gaurava          | 2.00 1.00    | 1.00±1.00*   | 1.90 1.10    |
|                  | (n=13)       | (n=17)       | (n=12)       |
| Jwara            | 0.60 0.30    | 0.30±0.09*   | 0.57 0.28    |
|                  | (n=17)       | (n=13)       | (n=17)       |
| Apaka            | 1.80 0.90    | 0.90±0.10*   | 1.80 0.90    |
|                  | (n=09)       | (n=09)       | (n=09)       |
| Sunta-Anganamana | 1.20 0.60    | 0.60±0.09*   | 1.20 0.60    |
|                  | (n=08)       | (n=08)       | (n=15)       |

BT = Before Treatment, AT = After Treatment, d±SE = Mean differences ± Standard Error of Mean
Table 9: Effect of therapy on general symptoms in 30 patients each group in Amavata (Rheumatoid arthritis) in group A, B & C. (n=90).

| Associated symptoms | Group ‘A’ (n=30) | Group ‘B’ (n=30) | Group ‘C’ (n=30) |
|---------------------|----------------|----------------|----------------|
|                     | BT  AT d±SE   | BT  AT d±SE   | BT  AT d±SE   |
| Daurbalya           | 1.80 0.90    | 0.90±0.06*    | 1.90 1.10    |
|                     | (n=22)       | (n=21)       | (n=26)       |
Agnimandya 1.60 0.80 0.80±0.13* (n=20) 2.00 1.33 0.66±0.33* (n=17) 2.00 1.00 1.00±1.00* (n=24)  
Kandu 0.80 0.40 0.40±0.09* (n=18) 0.50 0.33 0.17±0.14* (n=05) 0.02 0.10 0.10±0.31* (n=01)  
Vibandha 1.40 0.70 0.70±0.09* (n=14) 1.67 0.93 0.73±0.40* (n=14) 1.85 0.77 1.08±0.32* (n=12)  
Kukshishula 1.00 0.50 0.50±0.09* (n=05) 1.36 0.64 0.73±0.48* (n=19) 1.42 0.75 0.67±0.16* (n=09)  
Antrakujana 0.50 0.20 0.30±0.09* (n=03) 0.70 0.30 0.40±0.16* (n=04) 1.10 0.50 0.60±0.17* (n=09)  
Anaha 0.20 0.10 0.10±0.06* (n=05) 1.64 0.82 0.82±0.09* (n=09) 1.80 0.90 0.90±0.10* (n=09)  
Daha 0.50 0.20 0.20±0.08* (n=14) 0.50 0.20 0.30±0.13* (n=10) 0.50 0.20 0.20±0.13* (n=11)  
Hridgraha ( 0.01 0.00 0.10±0.06* (n=01) - - - - - -  
Nidra Viparyaya 0.80 0.50 0.30±0.09* (n=13) - - - 0.8 0.50 0.30±0.15* (n=04)  
Ushnata around joints 1.82 0.82 1.10±0.06* (n=10) - - - 2.00 0.90 1.10±0.06* (n=22)  

| Ring Test | Group 'A' (n=30) | Group 'B' (n=30) | Group 'C' (n=30) |
|-----------|-----------------|-----------------|-----------------|
|           | BT   | AT   | d±SE | BT   | AT   | d±SE | BT   | AT   | d±SE |
| Index     | 22.80 | 21.80 | 1.00±* (n=10) | 20.70 | 19.10 | 1.60±0.32* (n=30) | 22.80 | 21.80 | 1.00±0.32* (n=30) |
| Middle    | 23.90 | 22.90 | 1.00±* (n=10) | 24.70 | 22.80 | 1.90±0.18* (n=30) | 23.90 | 22.90 | 1.00±0.32* (n=30) |
| Little    | 05.20 | 04.90 | 0.30±0.28* (n=03) | 10.20 | 09.20 | 1.00±0.47* (n=15) | 05.20 | 04.90 | 0.30±0.28* (n=13) |

BT = Before Treatment, AT = After Treatment, d±SE = Mean differences ± Standard Error of Mean

Table 10: Effect of therapy on associated symptoms in 30 patients each group of Amavata (Rheumatoid arthritis) in group A, B & C. (n=90).
A Comparative Clinical Study on Vatariguggulu and Panchakarma Therapy with Special Reference to Kshara Basti and Virechana Karma in the Management of Amavata (Rheumatoid Arthritis)

Table 12: Effect of therapy on hematological parameters in 30 patients each group of Amavata (Rheumatoid arthritis) in group A, B & C. (n=90).

Table 13: Effect of therapy on biochemical parameters in 30 patients each group of Amavata (Rheumatoid arthritis) in group A, B & C. (n=90).

Table 14: Overall Effect of Vatari Guggulu, virechan karma & Kshara vasti in group A, B & C. (n=90)

Discussion

Amavata is one of the important areas of diseases which is being described in various Ayurvedic texts emphasizing different aspects of therapies, covering both pacifying (Samana) and purifaction (Sodhana) measures. The disease can be compared broadly with modern disease rheumatoid arthritis, to similarities in manifestation of clinical features. Rheumatoid arthritis (RA), the most common form of chronic inflammatory polyarthritis, represents a significant health burden in the developed world. The damage and deformity of the synovial joints characteristic of RA most commonly develops in the sixth decade but can occur at any age and will usually require treatments and interventions for the rest of an individual’s life [11]. Rheumatoid arthritis has a worldwide prevalence of approximately 1% (prevalence is the number of cases occurring in a population at a given
time) and is consistently observed to affect women 2–3 times more frequently than men. The occurrence of RA is not, however, the same throughout the world [12]. Prevalence rates are low in the less developed and rural parts of the world and it has been suggested that RA is a modern disease, its appearance seeming to coincide with industrialisation or urbanization [13]. Rheumatic diseases are a major cause of morbidity in India. Musculoskeletal pain is prevalent in 6.4%-23.6% of the Indian population. The most common causes of impaired quality of life due to musculoskeletal pain are the duration of symptoms, pain in shoulders and hand, and back pain. The most prevalent rheumatic problems are non-specific musculoskeletal complaints (4.25%-6.25%), osteoarthritis (4.39%-6.25%, of which knee osteoarthritis comprised 3.34%-4.42%) and soft tissue rheumatism 1.31%-3.77%. Inflammatory rheumatic diseases had a prevalence of less than 1% each (rheumatoid arthritis 0.34%-0.67%, undifferentiated inflammatory arthritis 0.22%-0.76%, spondyloarthritis 0.23%- 0.3%, gout 0.04%-0.13% and lupus 0.02%) [14]. Inspite of many advancement of treatment has been developed by modern medical sciences but most of these can limit the disease process to a certain extent and is unable to re-establish the physiological activities. Moreover, most of these treatments may cause serious adverse effects like gastric irritations (e.g., NSAIDs), immune-suppression (e.g., corticosteroids), etc.

Treatment of Amavata is described classically in many texts of Ayurveda like Bhavaprakash Nighantu, Bangasen Samhita, Sharamagadhara Samhita, etc. However, most scientifically the principle of management has been described in Chakraduttam, written during 16th century AD [15]. The classical description of the principle of management of Amavata according to Ayurveda is as follows-

- Lamghana (lightening therapy) and Swedanam (fomentation measure) are rendered for dissolution of ‘Ama’ vis-à-vis auto-immunological changes; drugs and diets having Tikta (bitter taste) and Katu (pungent taste) are helpful for kindling power of digestion so that the progress of disease can be arrested by preventing initiation of further pathogenesis process and the symptoms as well as complications can be pacified by means of specific purification (Panchakarma) therapy like Virechana and Vasti. Kshara vasti is the specific variety of purification therapy mentioned in Ayurveda for Amavata only. Kshara Basti comprises of Saindhava, Guda, Chinchha, Shatavaha and Gomutra. In this Basti, maximum quantity is of Gomutra, which is having Kshara Guna. Kshara has the property of Vishoshana, which are antagonistic to Ama and is very much required in the conditions like Amavata [16,17]. Kshara vasti may have probability of aggravation of Vata and that can be combated by Vatashamaka drug guggulu, specifically Vatariguggulu.

The present research work of Amavata was designed on the basis of the above mentioned hypothesis for its scientific validation utilizing some modern parameters in comparison with fundamental Ayurvedic theories. In the present context of study it was observed that out of three groups, the first one comprising of ‘Kshara Vasti’ (medicated alkaline enema), and ‘Vatariguggulu’ (Ayurvedic drugs composed with Commiphora wightii Linn., Ricinus communis Linn., Terminalia chebula Linn., Phyllanthus emblica Linn., Terminalia bellerrica Linn. and sulphur) was found to be best among other two groups comprises some fractions of the treatment. There were highly significant (p<0.001) improvement of subjective parameters like Sandhishula (pain in joints), Sandhgiraha (stiffness of joints), Sparshasahyata (tenderess), Daurbalya (general weakness), Agnimandya (loss of appetite), Hridgraha (cardiac hypo- dynamicity), etc. All
these physical changes with first group of treatment within 30 days of therapy was well compensated (p<0.001) with objective findings like routine blood examination including ESR, RA-factors and antinuclear antibodies. It was observed by overall observation that in spite marked improvement were not observed with this treatment in selected 30 cases of rheumatoid arthritis but 73% moderate improvement (22 patients) and 27% mild improvement (08 patients) were observed with this classical regimen of Ayurvedic therapy described in Chakraduttam. The Ayurvedic justification behind this improvement were due to (i) pacification of Ama by Lamghana and Swedana, (ii) dissolution of pathological products i.e., Amavista by means of Kshara Vasti and (iii) pacification of aggravated vata by means of Vatari Guggulu. On the other hand, the main pathology of rheumatoid arthritis is inflammation due to auto-immune reaction, which could be combated by anti-oxidant property of triphala (Terminalia chebula Linn., Phyllanthus emblica Linn., Terminalia bellirica Linn.) and anti-inflammatory activity by Commiphera wightii and Ricinus communis as reported in various modern research outcome. The Kshara Vasti and Virechana varieties of Panchakarma therapy are solely responsible for elimination of noxious pathological products of disease process deposited in many parts of the body so that the antigen-antibody reactions due to auto-immune mechanism could be mitigated. Inspite, Virechana is one of major procedure of therapeutics designed by Chakra Dutta for the management of ‘Amavata’ but by Ayurvedic pharmacodynamic nature of this therapy, it is responsible to eliminate ‘pitta’dosha. The motto of virechan therapy as designed by Chakra Pani Dutta is probably to eliminate pitta, if it is superimposed with vata & kapha vis-a-via Ama. In the present contexts, the prakriti of patients were found to be vata-kapha predominant and therefore addition of Virechana in Group c was not found to be satisfactory. It is, therefore, may be concluded that the Ayurvedic module of combination therapy of pacification and purification can be considered as one of the best model of treatment for control and pacification of the incurable disease Amavata vis-à-vis rheumatoid Arthritis.

Conclusion

The present research work reveals that Amavata (Rheumatoid Arthritis) is a debilitating disease which is not only incurable but may also alter the life style. A best way of treatment is needed, preferably by natural way, to control the disease process so that the life style may be maintained. It has been observed from the current research work that combination of Ayurvedic therapeutic module possessing Kshara Vasti and Vatari Guggulu can be the suitable choice to satisfy the primary objects of the treatment for Amavata (Rheumatoid Arthritis).

References

1. Shruthi S, Ashvini MK, Lohith BA, Uday S (2017) Effect of rasnadi churna basti in the management of Amavata in clinical correlation with rheumatoid arthritis – a clinical study, Int Ayur Med J 5(8): 2802-2811.

2. (1995) Madhava Nidana: Madhavakara with Madhukosha commentary by Vijay Rakshita and Shreekanta Datta and Atanka Darpana commentary by Vaidhya V, 5th (Edn.), Nirmaya Sagar Press, Bombay.

3. (1987) Bhaishajya Ratnavali: Govinda Das with Vidyotini Hindi commentary by Ambikadatta Shastri, (Ed.), Rajeshvar Datta Shastri, Chaukhambha Sanskrit Sansthana.

4. (1983) Davidson’s Principle and Practice of Medicine. & Dorland’s Pocket Medical Dictionary, 23rd (Edn.), Published by Oxford and IBH Publication Co., New Delhi, India.

5. (1987) Braunweld and Isselbacher: Harrison’s Principles of Internal Medicine, 11th (Edn.), Mc. Grawhill Book Company, New-york.

6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1987) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3): 315-324.

7. (2000) Charaka Samhita: With Ayurveda Dipika commentary of Chakrapani, edited by Y.T. Acharya, Chaukhambha Surbharati Prakashan, Varanasi & (2000) Charaka Samhita: Text with English translation, edited & translated by PV Sharma, 5th (Edn.), Chaukhambha Orientalia, Varanasi.

8. Madhavakara, Madhava Nidana, Acharya Yadavji Trikamji, Chaukhambha Sanskrit Series, Varanasi.

9. Sharma PV (1982) Dravya Guna Vidyana, Chaukhambha Sanskrit Series, Varanasi, pp: 9.

Ashis KD and Tuhin KB. A Comparative Clinical Study on Vatariguggulu and Panchakarma Therapy with Special Reference to Kshara Basti and Virechana Karma in the Management of Amavata (Rheumatoid Arthritis). J Nat Ayurvedic Med 2017, 1(2): 000110.
10. Mahesh R, Bhuva S, Begum VM (2009) Effect of Terminalia chebula aqueous extract on oxidative stress and antioxidant status in the liver and kidney of young and aged rats. Cell Biochem Funct 27(6): 358-363.

11. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, et al. (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9): 2569-2581.

12. Symmons DP, Silman AJ (2003) The Norfolk Arthritis Register (NOAR). Clin Exp Rheumatol 21(5 Suppl 31): S94-S99.

13. Abdel-Nasser AM, Rasker JJ, Valkenburg HA (1997) Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Semin Arthritis Rheum 27(2): 123-140.

14. Worthington J, Barton A, John SL (2006) The epidemiology of rheumatoid arthritis and the use of linkage and association studies to identify disease genes. In: The Hereditary Basis of Rheumatic Disease, Holmdahl, R (Edn.), Birkhauser Verlag, Basel, Switzerland, pp: 9-28.

15. Misra DP, Agarwal V, Negi VS (2016) Rheumatology in India: A Bird’s Eye View on Organization, Epidemiology, Training Programmes and Publications. J Korean Med Sci 31(7): 1013-1019.

16. (2002) Chakrapanidatta, Chakradatta Amavata Chikitsa Adhyaya, 25/ 24 edited by Pt. Brahmarshankar Mishra, 5th (Edn.), Chaukhambha Sanskrit Series Office, Varanasi, pp: 228.

17. Thanki K, Bhatt N, Shukla VD (2012) Effect of Kshara Basti and Nirgundi Ghana Vati on Amavata (Rheumatoid Arthritis). Ayu 33(1): 50-53.